HUMAN RETROVIROLOGY: HTLV

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

HUMAN RETROVIROLOGY: HTLV

Human Retrovirology: HTLV. Blattner WA, ed. New York, Raven, 484 p., 1990.. Unique Identifier : AIDSLINE ICDB/92677530
Anonymous; No affiliation given

Abstract: Isolation and characterization of the first human retrovirus (human T-cell lymphotropic virus type I; HTLV-I) in 1980 culminated a search begun in the early decades of the century and propelled rapid progress, including recognition of the AIDS-causing human immunodeficiency virus (HIV-I). This book reviews a decade of progress made and new insights gained into disease causation. In sections on pathogenesis, virology, clinical manifestations, epidemiology, and serology and diagnosis, the volume provides data from a conference held in February 1989 in Port of Spain, Trinidad and Tobago. These topics are included: models of retroviral leukemogenesis; neurologic diseases associated with infection by retroviruses; molecular basis of viral persistence; HTLV host cell range and its receptor; molecular variation of HTLVs and clinical associations; immunologic and virologic studies in HTLV-I-associated myelopathy (HAM)/tropical spastic paraparesis (TSP); constitutive expression of lymphotoxin (tumor necrosis factor beta) in HTLV-I-infected cell lines; HTLV-II infection in iv drug abusers with concomitant infections with HTLVs and HIV; serologic and immunologic aspects and isolation of HTLV-I strains from adult T-cell leukemia (ATL) and HAM/TSP in African and West Indian patients; HTLV-V; WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP; TSP clinical features; clinical and laboratory diagnosis of TSP and HAM; peripheral neuropathies and myositis associated with HTLV I INFECTion; epidemiologic perspectives of HTLV-I, modes of transmission and their relation to patterns of seroprevalence; genetic and immunologic determinants of HTLV-1-associated diseases; clinical, epidemiologic, and immunovirologic observations of HAMs in Western Europe and Tropical Africa; HTLV-I/II and blood transfusion in the United States; implication for disease in maternal-infant transmission; Public Health Service criteria for serologic confirmation of HTLV-I/II infections; particle agglutination assay in detecting low-titer HTLV-I antibodies; initial evaluation of a recombinant HTLV-1 gp21 enzyme immunoassay; mapping epitopes on HTLV-1 envelope glycoprotein; and antibody responses to different regions of HTLV-I gp61 in asymptomatic carriers, ATL patients, and individuals with TSP.

Keywords: Acquired Immunodeficiency Syndrome/COMPLICATIONS/MICROBIOLOGY Adult Blood Transfusion/ADVERSE EFFECTS Female Human HIV Seroprevalence HIV-1/IMMUNOLOGY/*ISOLATION & PURIF HTLV-I/IMMUNOLOGY/*ISOLATION & PURIF HTLV-I Infections/ETHNOLOGY/EPIDEMIOLOGY/*MICROBIOLOGY/ TRANSMISSION HTLV-II Infections/TRANSMISSION Immunologic Techniques Infant, Newborn Leukemia, T-Cell, HTLV-II-Associated/COMPLICATIONS Male Maternal-Fetal Exchange Paraparesis, Tropical Spastic/IMMUNOLOGY/MICROBIOLOGY Pregnancy Receptors, HIV Substance Abuse, Intravenous/COMPLICATIONS MONOGRAPH
920228
M9220894

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .